

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/250030 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 31/7125 (2006.01) *A61P 35/04* (2006.01)
A61K 39/39 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2024/032311

(22) International Filing Date:

03 June 2024 (03.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/470,653 02 June 2023 (02.06.2023) US
63/546,424 30 October 2023 (30.10.2023) US

(88) Date of publication of the international search report:

13 February 2025 (13.02.2025)

(71) Applicant: **TRISALUS LIFE SCIENCES, INC.**
[US/US]; 6272 West 91st Avenue, Westminster, CO 80031
(US).

(72) Inventors: **KATZ, Steven, C.**; 150 Fernwood Drive, East
Greenwich, RI 02818 (US). **COX, Bryan, F.**; 3472 Big Sky
Dr., Muscatine, IA 52761 (US). **JAROCH, David, Ben-
jamin**; 7630 Barbara Ann Drive, Arvada, CO 80004 (US).

(74) Agent: **LEE, Wan, Chieh**; Haug Partners LLP, 745 Fifth
Avenue, 10th Floor, New York, NY 10151 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS OF TREATING UVEAL MELANOMA LIVER METASTASES WITH A THERAPEUTICALLY EFFEC-
TIVE COMBINATION OF ONE OR MORE CHECKPOINT INHIBITORS AND A TOLL-LIKE RECEPTOR 9 AGONIST

(57) Abstract: A method for treating uveal melanoma liver metastases in a human subject. The method comprises administering to the subject a therapeutically effective combination of one or more checkpoint inhibitors and a toll-like receptor 9 (TLR9) agonist having the structure: 5'-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3' (SEQ ID NO: 1). The one or more checkpoint inhibitors are systematically administered to the subject and the TLR9 agonist is locally administered to the liver of the subject via hepatic artery infusion at a dose sufficient to provide a concentration in the liver that is therapeutically effective in combination with the checkpoint inhibitor.



WO 2024/250030 A3